Pliant Therapeutics, Inc. · NASDAQ:PLRX
Pliant Therapeutics — ERS Congress 2024
10 slides from Pliant Therapeutics's conference presentation, September 2024
Slide 1: Safety and tolerability of bexotegrast in Phase 2 trials of IPF and PSC
Safety and tolerability of bexotegrast in Phase 2 trials of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) Gregory P. Cosgrove, MD, Richard Pencek, PhD, Chris N. Barnes, PhD, Annie Clark, PharmD, PhD, Hardean E. Achneck, MD, Éric A. Lefebvre, MD
Slide 2: Conflict of Interest Disclosure
Conflict of Interest Disclosure ❑ I have no real or perceived conflicts of interest that relate to this presentation. ❑ I have the following real or perceived conflicts of interest that relate to this presentation: Affiliation / Financial interest Commercial company Grants/research support: Honorari
Slide 3: Background and Objectives
Background and Objectives αvβ6 and αvβ1 Integrins Promote Fibrosis • TGF-β is a central driver of fibrosis1,2 Through Activation of TGF-β1,2,a • Systemic TGF-β blockade carries toxicity risks2 Bexotegrast • Activation of latent TGF-β by αvβ6 (lung epithelial cells, (PLN-74809) injured cholangiocytes
Slide 4: Studies Included in the Safety Population
Studies Included in the Safety Population Post Primary Endpoint Phase 2 Studies ≥12 Weeks (N=236)a ≥24 Weeks (N=65) • To date, over 700 participants have been exposed to bexotegrast in unblinded and NCT04396756 Bexotegrast 40 mg Bexotegrast 80 mg blinded studies (INTEGRIS-IPF) Phase 2a R Bexotegrast
Slide 5: Baseline Demographics
Baseline Demographics Phase 2 Studies ≥12 Weeks Treatment Duration (N=236) 58.2 Mean years of age 58.8 Mean years of age 74.6% Male 83.6% Male 92.1% White 90.2% White 26.6 Mean BMI (kg/m2) 26.4 Mean BMI (kg/m2) Bexotegrast (n=177) Placebo (n=61) BMI, body mass index.
Slide 6: Safety Summary
Safety Summary Phase 2 Studies ≥12 Weeks Treatment Duration (N=236) 80 Unrelated to study drug 72.9 68.9 70 Related to study drug 16.9 60 26.2 Participants, % 50 40 30 56.0 20 47.2 7.3 9.8 6.6 10 1.1 3.3 4.5 6.2 6.5 4.5 6.6 0 BEXO PBO BEXO PBO BEXO PBO n=177 n=61 n=177 n=61 n=177 n=61 TEAEs Grade ≥3
Slide 7: Most Frequently Reported TEAEs
Most Frequently Reported TEAEs TEAEs In Participants with Treatment Duration ≤12 Weeks TEAEs In Participants with Treatment Duration >12 Weeksa Most frequent TEAEs (n≥10) IPF- and PSC-specific TEAEs Most frequent TEAEs (n≥4) IPF- and PSC-specific TEAEs 14 14 12.2 (n=6) 11.8 11.3 (n=2) 10.7 12 (n=20)
Slide 8: Conclusions and Future Research
Conclusions and Future Research Bexotegrast was well tolerated in participants in 2 Phase 2 studies ≥12 weeks in duration • The safety profile of bexotegrast was similar for participants treated for ≥12 weeks compared to those treated for a shorter duration The most frequently reported TEAE in bexot
Slide 9: ERS Congress 2024, 7-11 September, Vienna
@ ERS CONGRESS] 2024 7-11 September | Vienna, Austria
Slide 10: References
References 1 Saito A, et al. Int J Mol Sci. 2018;19(8):2460. 2 Decaris ML, et al. Respir Res. 2021;22(1):265. 3 Reed NI, et al. Sci Transl Med. 2015;7(288):288ra79. 4 Munger JS, et al. Cell. 1999;96(3):319-328. 5 Horan GS, et al. Am J Respir Crit Care Med. 2008;177(1):56-65. 6 Saini G, et al. Eur Re